Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Ruxience [legacy through FY23] by Quarter
Ruxience (rituximab biosimilar) [legacy through FY23] — Worldwide reported YoY (%) (%)
Pfizer Ruxience [legacy through FY23]: -13.0% in Q4 2023, up 19.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
“|| Ruxience | 88 | 101 | (13%) | (12%) | 62 | 83 | (25%) | 26 | 18 | 43% | 46%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Ruxience [legacy through FY23] (%), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/ruxience-leg-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.